Now, the person making the call is somebody somewhere who works for (the insurance company). It’s not my physician, who’s an ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...

Merck & Co., Inc. (NYSE:MRK) is one of Goldman Sachs top healthcare stocks. On March 3 at the TD Cowen 46th Annual Health Care Conference, Merck & Co., Inc. (NYSE:MRK) unveiled strategic initiatives ...

Side effects of Opdivo vs. Keytruda Both Opdivo and Keytruda treat certain types of cancer. They also belong to the same medication class. Because of this, these drugs can cause some of the same side ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...